Santhera closes Juvantia acquisition
This article was originally published in Scrip
Executive Summary
The acquisition of Finnish company Juvantia Pharma by Santhera Pharmaceuticals of Switzerland has closed, triggering a payment of $4 million from Santhera's partner Biovail.